Skip to main content

Receptor Subtype Abundance as a Tool for Effective Intracellular Signalling

Buy Article:

$68.00 + tax (Refund Policy)

The regulation of heart function is one of the essentials for the survival of organism. Therefore, the effective mechanisms of regulation can minimize the energy requirements and improve the ability to react to different needs on time and appropriately .

Two receptor types, β-adrenoceptors and muscarinic receptors, with almost antagonistic function, are “basic regulators” of the heart parameters. It is relevant to mention that beside the main adrenoceptors and muscarinic receptors subtypes (β1- and M2-subtype), other minor subtypes that regulate heart function, i.e. β2-, β3-adrenoceptors, α1-adrenoceptors and minor subtypes of muscarinic receptors (M1, M3 and M5) are present in the heart. In this regard is intriguing that just two catecholamines (adrenaline, noradrenaline) have many “targets” - receptors that differ so much in the functional consequences of their activation: while β1- and β2-adrenoceptors cause cardiostimulation, β3-adrenoceptors are responsible for cardioinhibition and α1-adrenoceptors contribute to enhanced inotropy. Similarly, some data show that other muscarinic receptors than M2 muscarinic subtype, are expressed in the heart and these minor subtype(s) can contribute to the heart regulation in similar way as β3-adrenoceptors to the catecholamine action.

Taken together, regulation of heart function through different receptor subtypes and using homologous and heterologous regulation can represent an effective tool for coping with permanently changing environmental conditions.

Keywords: Adrenoceptors; G protein coupled receptor regulation; heart; muscarinic receptors

Document Type: Research Article

Publication date: 01 March 2008

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content